AIHTA - News

©elenabsl

Announcement

Framework for reimbursement decisions of digital health technologies (mHealth) and its (retrospective) application on selected examples

Digital health applications have the potential to improve disease monitoring and management. For the majority of available digital health applications, however, there is little evidence of (medical, organizational or economic) benefit. The thorough evaluation of a digital health application requires additional technology-specific domains. Decision-makers are thus faced with new challenges in the evaluation of these applications.

The aim of this report was to provide guidance to funding institutions and manufacturers as to what evidence is expected for which type of digital health application. For this purpose, the applicability of currently available assessment frameworks for digital health applications was examined.

Publication: HTA Projektbericht No. 134: https://eprints.aihta.at/1279
Contact: Reinhard Jeindl, Claudia Wild

More...

©Juan Gärtner

Announcement

Horizon Scanning in Oncology - Fact Sheets

We are pleased to introduce our three new HSO Fact Sheets.

Fact Sheet No. 25 (October 2020)
Blinatumomab (Blincyto®) for the treatment of patients with Philadelphia chromosome positive B-precursor acute lymphoblastic leukaemia (ALL)

Fact Sheet No. 26 (October 2020)
Nivolumab (Opdivo®) as monotherapy for the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OESCC)

Fact Sheet No. 27 (October 2020)
Autologous anti-CD19-transduced CD3+ cells (Tecartus®) for the treatment of relapsed or refractory mantle cell lymphoma (MCL)

More...

@ Mike Fouque

Announcement

Covid-19: HSS/ Horizon Scanning Living Document (v08 November 2020)

The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.

All work steps are conducted in close international (European) cooperation.

Publications:

Policy Brief No. 002: http://eprints.aihta.at/1234/

Contact: Claudia Wild

More...

Newsletter

Note: this content is only available in German.

Inhalt

Zur Druckversion...

©AungMyo

Announcement

Home-Treatment in Child and Adolescent Psychiatry: An Analysis of the Effectiveness and Possible Implementation in Austria

The Austrian child and adolescent psychiatric care landscape is characterised by substantial deficits on the intramural, as well as, on the extramural level. To overcome these supply shortfalls alternative outreach approaches, such as home-treatment, can be introduced to facilitate the reduction of hospitalisations. In this context, the present report aimed to systematically characterise international home-treatment-models considering their effectiveness and safety in the area of child and adolescent psychiatry. In addition, the fundamental challenges of implementing such treatment approaches were examined, taking into account the current Austrian care situation.

Publication: AIHTA Project report No. 129: http://eprints.aihta.at/1275/

Contact: Sarah Wolf, Nicole Grössmann

More...

©Juan Gärtner

Announcement

Horizon Scanning in Oncology - Fact Sheets

We are pleased to introduce our five new HSO Fact Sheets.

Fact Sheet No. 20 (September 2020)
Atezolizumab (Tecentriq®) plus bevacizumab for the treatment of advanced or unresectable hepatocellular carcinoma (HCC)

Fact Sheet No. 21 (September 2020)
Nivolumab (Opdivo®) plus ipilimumab (Yervoy®) and chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC)

Fact Sheet No. 22 (September 2020)
Niraparib (Zejula®) in patients with newly diagnosed advanced ovarian cancer

Fact Sheet No. 23 (September 2020)
Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC)

Fact Sheet No. 24 (September 2020)
Olaparib (Lynparza®) plus bevacizumab as first-line maintenance treatment in patients with ovarian cancer

More...

Newsletter

Note: this content is only available in German.

Inhalt

Zur Druckversion...

@ Mike Fouque

Announcement

Covid-19: HSS/ Horizon Scanning Living Document (v07 October 2020)

The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.

All work steps are conducted in close international (European) cooperation.

Publications:

Policy Brief No. 002: http://eprints.aihta.at/1234/

Contact: Claudia Wild

More...

Newsletter

Note: this content is only available in German.

Inhalt

Zur Druckversion...

©Mike Fouque

Announcement

Covid-19: HSS/ Horizon Scanning Living Document (v06 September 2020)

he establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.

All work steps are conducted in close international (European) cooperation.

Publications: